Compare Biocon with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PROCTER & GAMBLE HEALTH - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PROCTER & GAMBLE HEALTH BIOCON /
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 32.8 16.9 193.7% View Chart
P/BV x 3.9 6.8 57.3% View Chart
Dividend Yield % 0.3 7.0 3.6%  

Financials

 BIOCON    PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    BIOCON
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
BIOCON /
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs7073,549 19.9%   
Low Rs5541,301 42.6%   
Sales per share (Unadj.) Rs91.9511.4 18.0%  
Earnings per share (Unadj.) Rs16.761.3 27.3%  
Cash flow per share (Unadj.) Rs24.274.0 32.7%  
Dividends per share (Unadj.) Rs1.00440.00 0.2%  
Dividend yield (eoy) %0.218.1 0.9%  
Book value per share (Unadj.) Rs101.6927.8 11.0%  
Shares outstanding (eoy) m600.0016.60 3,614.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.7 144.7%   
Avg P/E ratio x37.739.6 95.4%  
P/CF ratio (eoy) x26.132.8 79.6%  
Price / Book Value ratio x6.22.6 237.3%  
Dividend payout %6.0717.9 0.8%   
Avg Mkt Cap Rs m378,33040,257 939.8%   
No. of employees `0006.11.1 540.7%   
Total wages/salary Rs m11,6531,313 887.7%   
Avg. sales/employee Rs Th8,994.37,486.7 120.1%   
Avg. wages/employee Rs Th1,900.71,157.6 164.2%   
Avg. net profit/employee Rs Th1,635.3897.2 182.3%   
INCOME DATA
Net Sales Rs m55,1448,490 649.5%  
Other income Rs m1,444244 592.0%   
Total revenues Rs m56,5888,734 647.9%   
Gross profit Rs m15,8831,482 1,072.0%  
Depreciation Rs m4,478211 2,120.3%   
Interest Rs m7090-   
Profit before tax Rs m12,1401,514 801.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m2,123563 377.4%   
Profit after tax Rs m10,0261,017 985.5%  
Gross profit margin %28.817.5 165.0%  
Effective tax rate %17.537.1 47.1%   
Net profit margin %18.212.0 151.7%  
BALANCE SHEET DATA
Current assets Rs m48,22815,343 314.3%   
Current liabilities Rs m30,3761,960 1,549.6%   
Net working cap to sales %32.4157.6 20.5%  
Current ratio x1.67.8 20.3%  
Inventory Days Days6849 140.1%  
Debtors Days Days8628 300.6%  
Net fixed assets Rs m64,1301,209 5,303.1%   
Share capital Rs m3,000166 1,807.2%   
"Free" reserves Rs m57,98015,235 380.6%   
Net worth Rs m60,98015,401 395.9%   
Long term debt Rs m15,7660-   
Total assets Rs m121,92417,595 693.0%  
Interest coverage x18.1NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 93.7%   
Return on assets %8.85.8 152.3%  
Return on equity %16.46.6 248.9%  
Return on capital %16.810.3 163.3%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5061,636 947.6%   
Fx outflow Rs m10,3994,368 238.1%   
Net fx Rs m5,107-2,732 -186.9%   
CASH FLOW
From Operations Rs m11,546-1,304 -885.6%  
From Investments Rs m-7,13812,697 -56.2%  
From Financial Activity Rs m-2,417-301 804.3%  
Net Cashflow Rs m2,10311,093 19.0%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 51.8 39.8%  
Indian inst/Mut Fund % 8.4 18.2 46.2%  
FIIs % 10.7 1.0 1,070.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 29.1 68.4%  
Shareholders   109,995 28,591 384.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 202 Points Lower; Britannia and Mahindra & Mahindra Among Top Nifty Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 23, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS